Similar GeneSets :: GeneWeaver

GeneSets Sharing a Publication with GS75584

				GeneSet Title
Tier III	Mouse		50 Genes	GS75580 Differential gene expression between vehicle-treated C57 and DBA strains
				LABEL: vehicle c57 dba DESCRIPTION: from Grice et al., 2007
Tier III	Mouse		34 Genes	GS75582 Genes showing differential expression between morphine-treated C57 and DBA strains
				LABEL: morphine treated c57 dba DESCRIPTION: from Grice et al., 2007
Tier III	Mouse		5 Genes	GS75583 Genes showing differential expression between vehicle and morphine-treated DBA mice
				LABEL: vehicle morphine c57 dba DESCRIPTION: from Grice et al., 2007
Tier III	Mouse		705 Genes	GS75584 Genes showing main effect of strain between C57 and DBA mice
				LABEL: strain c57 dba DESCRIPTION: from Grice et al., 2007
Tier III	Mouse		137 Genes	GS75585 Genes showing main effect of morphine- and vehicle-treated C57 and DBA mice
				LABEL: treated c57 dba DESCRIPTION: from Grice et al., 2007
Tier III	Mouse		240 Genes	GS75586 Genes showing a strain by treatment interaction in C57 and DBA morphine- and vehicle-treated mice
				LABEL: strain treatment c57 dba DESCRIPTION: from Grice et al., 2007
Tier I	Mouse	DRG	41 Genes	GS86426 Table S1: The data provided represent genes showing differential expression. B. Genes showing differential expression between morphine-treated C57 and DBA strains. [DRG]
				LABEL: Chronic morphine - DBA/2J vs. C57BL/6 DESCRIPTION: Chronic morphine - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were between roughly 1-4% for results contrasting the two strains. (NIF Table ID 432 [335])
Tier I	Mouse	DRG	1 Genes	GS86618 Table 1: QPCR validation analysis of select neuronal mRNAs. [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Table ID 436 [339])
Tier I	Mouse	DRG	1 Genes	GS86632 Table 1: QPCR validation analysis of select neuronal mRNAs. [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Table ID 436 [340])
Tier I	Mouse	DRG	6 Genes	GS86690 Table S1: The data provided represent genes showing differential expression. C. Genes showing differential expression between vehicle and morphine-treated DBA. [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were significantly higher (roughly 20%) for contrasts within strains. (NIF Table ID 433 [336])
Tier I	Mouse	DRG	1 Genes	GS86862 Table 1: QPCR validation analysis of select neuronal mRNAs. [DRG]
				LABEL: Chronic morphine - DBA/2J vs. C57BL/6 DESCRIPTION: Chronic morphine - DBA/2J vs. C57BL/6 Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Table ID 436 [342])
Tier I	Mouse	DRG	56 Genes	GS86904 Table S1: The data provided represent genes showing differential expression. A. Genes showing differential expression between vehicle-treated C57 and DBA strains. [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were between roughly 1-4% for results contrasting the two strains. (NIF Table ID 431 [334])
Tier I	Mouse	DRG	857 Genes	GS86984 Table S2: The data provided represent genes showing differential expression using ANOVA. A. Genes showing main effect of strain. [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Two-way analysis of variance (ANOVA) using dChip, to identify genes with a main effect of strain, treatment, or with an interaction effect. P < 0.01 and no fold-effect requirement. (NIF Table ID 434 [337])
Tier I	Mouse	DRG	1 Genes	GS87093 Table 1: QPCR validation analysis of select neuronal mRNAs. [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Table ID 436 [341])
Tier I	Mouse	DRG	168 Genes	GS87119 Table S2: The data provided represent genes showing differential expression using ANOVA. B. Genes showing main effect of treatment. [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Two-way analysis of variance (ANOVA) using dChip, to identify genes with a main effect of strain, treatment, or with an interaction effect. P < 0.01 and no fold-effect requirement. (NIF Table ID 435 [338])
Tier I	Mouse	DRG	1 Genes	GS87371 Table 1: QPCR validation analysis of select neuronal mRNAs. (Whole Table) [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Method ID 339)
Tier I	Mouse	DRG	1 Genes	GS87372 Table 1: QPCR validation analysis of select neuronal mRNAs. (Whole Table) [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Method ID 340)
Tier I	Mouse	DRG	1 Genes	GS87373 Table 1: QPCR validation analysis of select neuronal mRNAs. (Whole Table) [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Method ID 341)
Tier I	Mouse	DRG	1 Genes	GS87374 Table 1: QPCR validation analysis of select neuronal mRNAs. (Whole Table) [DRG]
				LABEL: Chronic morphine - DBA/2J vs. C57BL/6 DESCRIPTION: Chronic morphine - DBA/2J vs. C57BL/6 Quantitative polymerase chain reaction Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Relative quantitation using the comparative threshold cycle (CT) method was performed in Microsoft Excel (ABI Technote #2: Relative Gene Expression Quantitation). P-values were calculated using two-way ANOVA carried out independently for each gene target. GAPDH was selected as a reference mRNA for comparative analysis based on its behavior in the microarray data set, showing no signal value differences in different strains. Normalized to the average expression in C57 under control conditions. There was a high correlation of the ratio of mRNA expression between the two strains as measured by microarray and by QPCR (Pearson's correlation coefficient, r>0.8, examining vehicle-treated mice). (NIF Method ID 342)
Tier I	Mouse	DRG	60 Genes	GS87375 Table S1: The data provided represent genes showing differential expression. (Whole Table) [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were between roughly 1-4% for results contrasting the two strains. (NIF Method ID 334)
Tier I	Mouse	DRG	45 Genes	GS87376 Table S1: The data provided represent genes showing differential expression. (Whole Table) [DRG]
				LABEL: Chronic morphine - DBA/2J vs. C57BL/6 DESCRIPTION: Chronic morphine - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were between roughly 1-4% for results contrasting the two strains. (NIF Method ID 335)
Tier I	Mouse	DRG	8 Genes	GS87377 Table S1: The data provided represent genes showing differential expression. (Whole Table) [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Used dChip algorithm (version 1.3). Invariant Set Normalization and PM-MM modeling; The nominal p value was determined using dChip (which down-weights unreliable expression data), testing whether the mean difference between two groups equals to zero by the unpaired t-test. mRNAs showing a P < 0.05 and greater than >= 1.7 fold change. Median False-Discovery Rate (FDR) estimates were significantly higher (roughly 20%) for contrasts within strains. (NIF Method ID 336)
Tier I	Mouse	DRG	857 Genes	GS87378 Table S2: The data provided represent genes showing differential expression using ANOVA. (Whole Table) [DRG]
				LABEL: Placebo - DBA/2J vs. C57BL/6 DESCRIPTION: Placebo - DBA/2J vs. C57BL/6 DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Two-way analysis of variance (ANOVA) using dChip, to identify genes with a main effect of strain, treatment, or with an interaction effect. P < 0.01 and no fold-effect requirement. (NIF Method ID 337)
Tier I	Mouse	DRG	168 Genes	GS87379 Table S2: The data provided represent genes showing differential expression using ANOVA. (Whole Table) [DRG]
				LABEL: Chronic morphine - Morphine vs. Placebo DESCRIPTION: Chronic morphine - Morphine vs. Placebo DNA microarray Change in mRNA expression Animals underwent surgery for subcutaneous implantation of either a control (Placebo to Morphine Base Implant Pellet) or morphine pellet (25 mg Morphine Base Implant Pellet) on the dorsal aspect of the neck. The composition of the pellets was identical (microcrystalline cellulose, 149 mg; magnesium stearate, 1.5 mg; colloidal silicon dioxide, 2.5 mg) except for the addition of 25 mg of purified morphine. While the animal was under anesthesia, a 1/4-inch slit was made in the skin, the pellet inse Two-way analysis of variance (ANOVA) using dChip, to identify genes with a main effect of strain, treatment, or with an interaction effect. P < 0.01 and no fold-effect requirement. (NIF Method ID 338)

GeneSets with the Same Publication

GeneSets Sharing a Publication with GS75584

Manage GeneSets

Analyze GeneSets

Manage Accounts

GeneWeaver Links

Policies

What seems to be the problem?

Description:

Name:

Email:

GeneSets with the Same Publication

GeneSets Sharing a Publication with GS75584

Add Selected GeneSets to Project(s)

The following GeneSet(s) will be added:

New Project Name:

No GeneSets Selected

You must select at least one GeneSet.

Manage GeneSets

Analyze GeneSets

Manage Accounts

GeneWeaver Links

Policies